Amgen strikes while its rival is down
With Mirati embroiled in a management overhaul Amgen moves to consolidate its upper hand.
Delays hit Sanofi
The Ameera-3 readout gets pushed back again, while fitusiran’s filing will not happen until 2024.
Agenus investors wake up to inevitability
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
Roche takes the Tim-3 battle to Novartis
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
Arrowhead pause raises more questions about lung delivery
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
New Glaxo: it’s all about the late-stage assets
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Medtronic’s Hugo still a long way from victor
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
